Sandra Silberman

13.5k total citations · 4 hit papers
38 papers, 6.8k citations indexed

About

Sandra Silberman is a scholar working on Oncology, Hematology and Genetics. According to data from OpenAlex, Sandra Silberman has authored 38 papers receiving a total of 6.8k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Hematology and 12 papers in Genetics. Recurrent topics in Sandra Silberman's work include Gastrointestinal Tumor Research and Treatment (9 papers), Glioma Diagnosis and Treatment (8 papers) and Cancer Treatment and Pharmacology (8 papers). Sandra Silberman is often cited by papers focused on Gastrointestinal Tumor Research and Treatment (9 papers), Glioma Diagnosis and Treatment (8 papers) and Cancer Treatment and Pharmacology (8 papers). Sandra Silberman collaborates with scholars based in United States, Switzerland and Poland. Sandra Silberman's co-authors include Saša Dimitrijević, George D. Demetri, Peter Roberts‎, Heikki Joensuu, Brian Druker, Christopher D.�M. Fletcher, Renaud Capdeville, Pekka Tervahartiala, David A. Tuveson and Maarit Sarlomo‐Rikala and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Sandra Silberman

36 papers receiving 6.6k citations

Hit Papers

Kinase Mutations and Imatinib Response in Patients With M... 2001 2026 2009 2017 2003 2001 2001 2001 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor
    2003 1.7k citations Michael C. Heinrich, Christopher L. Corless et al. Journal of Clinical Oncology profile →
  2. Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor
    2001 1.5k citations Heikki Joensuu, Peter Roberts‎ et al. New England Journal of Medicine profile →
  3. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study
    2001 975 citations Allan T. van Oosterom, Ian Judson et al. The Lancet profile →
  4. Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
    2001 830 citations Sandra Silberman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sandra Silberman United States 15 4.0k 3.5k 1.8k 1.8k 1.1k 38 6.8k
Saša Dimitrijević United States 24 4.8k 1.2× 4.3k 1.2× 1.7k 1.0× 2.1k 1.2× 1.4k 1.3× 49 8.4k
A. van Oosterom Belgium 34 4.2k 1.1× 3.1k 0.9× 1.8k 1.0× 1.7k 1.0× 610 0.5× 88 6.7k
Ajia Town United States 13 2.9k 0.7× 2.9k 0.8× 1.1k 0.6× 1.4k 0.8× 758 0.7× 17 5.3k
Jonathan C. Trent United States 48 5.1k 1.3× 3.5k 1.0× 2.5k 1.4× 2.2k 1.3× 376 0.3× 283 8.2k
Maria Dêbiec‐Rychter Belgium 59 7.5k 1.9× 4.2k 1.2× 2.7k 1.5× 2.5k 1.4× 663 0.6× 318 12.3k
Herlinde Dumez Belgium 35 2.3k 0.6× 1.2k 0.3× 1.7k 0.9× 781 0.4× 468 0.4× 145 4.8k
Agnieszka Woźniak Belgium 38 3.4k 0.9× 2.0k 0.6× 1.6k 0.9× 1.2k 0.7× 189 0.2× 188 5.2k
Scott M. Schuetze United States 43 6.4k 1.6× 1.3k 0.4× 3.3k 1.8× 1.3k 0.7× 370 0.3× 167 8.7k
Vivien Bramwell Canada 32 2.6k 0.7× 1.0k 0.3× 2.4k 1.3× 836 0.5× 219 0.2× 75 5.1k
Philippe A. Cassier France 43 3.2k 0.8× 801 0.2× 4.0k 2.2× 1.1k 0.6× 195 0.2× 295 7.4k

Countries citing papers authored by Sandra Silberman

Since Specialization
Citations

This map shows the geographic impact of Sandra Silberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Silberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Silberman more than expected).

Fields of papers citing papers by Sandra Silberman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Silberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Silberman. The network helps show where Sandra Silberman may publish in the future.

Co-authorship network of co-authors of Sandra Silberman

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Silberman. A scholar is included among the top collaborators of Sandra Silberman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Silberman. Sandra Silberman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Goldlust, Samuel, Burt Nabors, Sigmund Hsu, et al.. (2024). Phase 1 trial of TPI 287, a microtubule stabilizing agent, in combination with bevacizumab in adults with recurrent glioblastoma. Neuro-Oncology Advances. 6(1). vdae009–vdae009. 1 indexed citations
2.
Silberman, Sandra. (2024). RMTD-03 USE OF A BRAIN-PENETRATING ANTHRACYCLINE IN ANTHRACYCLINE-SENSITIVE BRAIN METASTASES: THE PROMISE OF BERUBICIN. Neuro-Oncology Advances. 6(Supplement_1). i33–i34.
3.
Zieliński, Rafał, et al.. (2023). Anthracycline-induced cardiotoxicity — are we about to clear this hurdle?. European Journal of Cancer. 185. 94–104. 58 indexed citations
4.
Croucher, Peter J.P., Maya Ridinger, Pamela S. Becker, et al.. (2023). Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Annals of Hematology. 102(11). 3049–3059. 6 indexed citations
5.
6.
Zeidan, Amer M., Maya Ridinger, Tara L. Lin, et al.. (2020). A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 26(23). 6132–6140. 57 indexed citations
7.
8.
Zhu, Jason, C DAVIS, Sandra Silberman, Neil L. Spector, & Tian Zhang. (2015). A role for the androgen receptor in the treatment of male breast cancer. Critical Reviews in Oncology/Hematology. 98. 358–363. 5 indexed citations
9.
Fitzgerald, Daniel P., David L. Emerson, Yongzhen Qian, et al.. (2012). TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells. Molecular Cancer Therapeutics. 11(9). 1959–1967. 69 indexed citations
10.
Heinrich, Michael C., Christopher L. Corless, George D. Demetri, et al.. (2003). Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor. Journal of Clinical Oncology. 21(23). 4342–4349. 1719 indexed citations breakdown →
11.
Capdeville, Renaud & Sandra Silberman. (2003). Imatinib: A targeted clinical drug development. Seminars in Hematology. 40(2 Suppl 2). 15–20. 22 indexed citations
12.
Stroobants, Sigrid, J. Goeminne, Saša Dimitrijević, et al.. (2003). 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec®). European Journal of Cancer. 39(14). 2012–2020. 373 indexed citations
13.
Johnson, Bruce E., Thomas Fischer, B. Fischer, et al.. (2003). Phase II study of imatinib in patients with small cell lung cancer.. PubMed. 9(16 Pt 1). 5880–7. 142 indexed citations
14.
Capdeville, Renaud, Sandra Silberman, & Saša Dimitrijević. (2002). Imatinib: the first 3 years. European Journal of Cancer. 38. S77–S82. 28 indexed citations
15.
Joensuu, Heikki, Christopher D.�M. Fletcher, Saša Dimitrijević, et al.. (2002). Management of malignant gastrointestinal stromal tumours. The Lancet Oncology. 3(11). 655–664. 452 indexed citations
16.
Apperley, Jane F., Martine Gardembas, Junia V. Melo, et al.. (2002). Response to Imatinib Mesylate in Patients with Chronic Myeloproliferative Diseases with Rearrangements of the Platelet-Derived Growth Factor Receptor Beta. New England Journal of Medicine. 347(7). 481–487. 449 indexed citations
17.
Joensuu, Heikki, Peter Roberts‎, Maarit Sarlomo‐Rikala, et al.. (2001). Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor. New England Journal of Medicine. 344(14). 1052–1056. 1525 indexed citations breakdown →
18.
Oosterom, Allan T. van, Ian Judson, Jaap Verweij, et al.. (2001). Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. The Lancet. 358(9291). 1421–1423. 975 indexed citations breakdown →
19.
Dezube, B. J., et al.. (1997). Tenidap Inhibits Replication of the Human Immunodeficiency Virus-1 in Cultured Cells. Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 14(1). 13–17. 2 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Saša Dimitrijević Breakdown of academic impact, for papers by A. van Oosterom Breakdown of academic impact, for papers by Ajia Town Breakdown of academic impact, for papers by Jonathan C. Trent Breakdown of academic impact, for papers by Maria Dêbiec‐Rychter Breakdown of academic impact, for papers by Herlinde Dumez Breakdown of academic impact, for papers by Agnieszka Woźniak Breakdown of academic impact, for papers by Scott M. Schuetze Breakdown of academic impact, for papers by Vivien Bramwell Breakdown of academic impact, for papers by Philippe A. Cassier
Rankless by CCL
2026